Synergistic modulation of cardiac lipid metabolism by Hedan Pill and Shexiang Baoxin Pill through the peroxisome proliferator‐activated receptor α–carnitine palmitoyltransferase 1A axis in experimental heart failure

Abstract Congestive heart failure (CHF) is associated with profound cardiac metabolic remodelling, particularly in lipid utilization. While Hedan Pill and Shexiang Baoxin Pill are traditional Chinese medicines with cardiovascular benefits, their synergistic mechanisms in CHF remain unclear. Network pharmacology and molecular docking were combined with in vivo validation using ApoE −/− mice fed a high‐fat diet and subjected to isoproterenol (ISO) treatment. Animals were allocated to seven groups: control, model, Entresto, Hedan Pill, Shexiang Baoxin Pill, Entresto + Hedan Pill, and Entresto + Shexiang Baoxin Pill. Cardiac function, serum lipids, myocardial histopathology, and protein expression of peroxisome proliferator‐activated receptor α (PPARα), carnitine palmitoyltransferase 1A (CPT1A) and sterol regulatory element‐binding protein 1c (SREBP‐1c) were assessed. Network analysis indicated convergence on the PPARα–lipid metabolism pathway, with strong binding affinities between several active compounds and PPARα (≤ −7.0 kcal mol −1 ). In vivo, Hedan Pill or ShexiangBaoxin Pill alone improved ejection fraction, reduced triglycerides, and alleviated fibrosis and lipid deposition. Compared with Entresto alone, both combination regimens further reduced serum triglycerides and LDL‐C, whereas ejection fraction did not differ significantly. Mechanistically, both agents upregulated myocardial PPARα and CPT1A while suppressing SREBP‐1c. Hedan Pill and Shexiang Baoxin Pill synergistically improve cardiac lipid metabolic homeostasis through the PPARα–CPT1A axis, thereby protecting against CHF‐induced myocardial injury. These findings provide physiological and mechanistic evidence supporting their translational potential as complementary interventions in CHF.

Authors

Institutions

Publication Details

Journal
Experimental Physiology
Published
2026-11-16
DOI
https://doi.org/10.1113/ep093334
Primary Topic
Peroxisome Proliferator-Activated Receptors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Synergistic modulation of cardiac lipid metabolism by Hedan Pill and Shexiang Baoxin Pill through the peroxisome proliferator‐activated receptor α–carnitine palmitoyltransferase 1A axis in experimental heart failure

Linjun Xie, Cheng Cao, Feng Wang, Lixin Wang et al.
1 links
Experimental Physiology
Peroxisome Proliferator-Activated Receptors
article

Synergistic modulation of cardiac lipid metabolism by Hedan Pill and Shexiang Baoxin Pill through the peroxisome proliferator‐activated receptor α–carnitine palmitoyltransferase 1A axis in experimental heart failure

Linjun Xie, Cheng Cao, Feng Wang, Lixin Wang, Xinyuan Ding, Zhang Qian, Xinxin Yan, Ping Li, Yu Wang, Guanghao Niu, Yanxia Yu, Yuan Li
article en

Abstract

Abstract Congestive heart failure (CHF) is associated with profound cardiac metabolic remodelling, particularly in lipid utilization. While Hedan Pill and Shexiang Baoxin Pill are traditional Chinese medicines with cardiovascular benefits, their synergistic mechanisms in CHF remain unclear. Network pharmacology and molecular docking were combined with in vivo validation using ApoE −/− mice fed a high‐fat diet and subjected to isoproterenol (ISO) treatment. Animals were allocated to seven groups: control, model, Entresto, Hedan Pill, Shexiang Baoxin Pill, Entresto + Hedan Pill, and Entresto + Shexiang Baoxin Pill. Cardiac function, serum lipids, myocardial histopathology, and protein expression of peroxisome proliferator‐activated receptor α (PPARα), carnitine palmitoyltransferase 1A (CPT1A) and sterol regulatory element‐binding protein 1c (SREBP‐1c) were assessed. Network analysis indicated convergence on the PPARα–lipid metabolism pathway, with strong binding affinities between several active compounds and PPARα (≤ −7.0 kcal mol −1 ). In vivo, Hedan Pill or ShexiangBaoxin Pill alone improved ejection fraction, reduced triglycerides, and alleviated fibrosis and lipid deposition. Compared with Entresto alone, both combination regimens further reduced serum triglycerides and LDL‐C, whereas ejection fraction did not differ significantly. Mechanistically, both agents upregulated myocardial PPARα and CPT1A while suppressing SREBP‐1c. Hedan Pill and Shexiang Baoxin Pill synergistically improve cardiac lipid metabolic homeostasis through the PPARα–CPT1A axis, thereby protecting against CHF‐induced myocardial injury. These findings provide physiological and mechanistic evidence supporting their translational potential as complementary interventions in CHF.

Experimental Physiology
Soochow University (CN), Suzhou Municipal Hospital (CN), The Fifth People’s Hospital of Suzhou (CN), Nanjing Medical University (CN)
Good health and well-being
Peroxisome Proliferator-Activated Receptors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon